Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The study titled A Phase 1/2 Open-Label, ...

Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

(“CSPC”) (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy designation by the Center for Drug ...

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, ...

Dr Anjali Pathak discusses four cases of skin cancer or pre-cancer - involving potentially malignant skin lesions - and their management ...

Aranscia® solutions help oncologists comply with new FDA warning label requiring  DPYD genetic testing in patients receiving select chemotherapies HOUSTON , Oct.

Heavy metals are dangerous at high levels, but treatments that remove can also be risky and only benefit certain patients. Chelation therapy is used to treat acute cases of lead poisoning and other ...

A sulfur-containing amino acid called cysteine could help cancer patients recover from gut damage caused by chemotherapy and ...

The HERCULES trial shows pembrolizumab plus chemotherapy produces a 39.4% response rate in advanced penile cancer, offering new treatment hope globally.